Publications

Links to all papers from the lab are organized by year of publication.

Preprints

A Blaisdell, S Bachl, LR Sandoval, C Ching, CJ Bowman, N Kale, M Prabandham, M Diolaiti, C Havig, R Advincula, N Lenci, Z Li, E Yamashita, CH Wang, S Zhang, Q Liu, P Achacoso, D Stibor, I Øynebråten, J Seo, A Ashworth, A Marson, CJ Ye, BA Malynn, J Eyquem, J Carnevale, A Ma. Base-editing a single missense mutation in A20 enhances CAR-T cell efficacy. bioRxiv. (2025)

‍

H Jung, P Devant, C Ching, M Ota, J Hamilton, Z Steinhart, W Ngo, LR Sandoval, JH Jung, D Xu, M An, E Urs, PA Chen, V Allain, T Tada, JK Nuñez, NR Landau, DR Liu, J Eyquem, JA Doudna, A Marson, J Carnevale. Virus-like particles enable targeted gene engineering and pooled CRISPR screening in primary human myeloid cells. bioRxiv. (2025)

‍

Q Liu, PA Chen, E Urs, S Zhang, MM Arce, CH Wang, Z Li, J Seo, N Kale, TN LaFlam, F Peng, E Shifrut, GM Allen, J Eyquem, K Fuh, SE Dodgson, JG Cyster, A Marson, J Carnevale. In vivo genome-wide CRISPR screens in human T cells to enhance T cell therapy for solid tumors. bioRxiv. (2025)

2026

H Jung, P Devant, C Ching, M Ota, E Dann, R Zhu, C Modak, A Vasquez-Ibarra, JR Hamilton, Z Steinhart, W Ngo, LR Sandoval, JH Jung, JHJ Lee, D Xu, M An, E Urs, PA Chen, V Allain, T Tada, LA Gilbert, BR Shy, JK Pritchard, JK Nuñez, NR Landau, DR Liu, J Eyquem, JA Doudna, A Marson, J Carnevale. Virus-like particles enable targeted gene engineering and pooled CRISPR screening in primary human myeloid cells. Nat Biotechnol (2026)

‍

Q Liu, PA Chen, E Urs, S Zhang, MM Arce, CH Wang, J Yan, VQ Nguyen, Z Li, J Seo, N Kale, F Peng, Y Luo, L Goudy, TN LaFlam, H Zhong, C Modak, E Dann, JH Jung, A Kirane, AB Warner, BB Quach, Z Good, BR Shy, E Shifrut, SP Bapat, GM Allen, J Eyquem, K Fuh, SE Dodgson, JG Cyster, A Marson, J Carnevale. In vivo genome-wide CRISPR screens of human T cells in solid tumours Nature (2026)

‍

WA Nyberg, PL Bernard, W Ngo, CH Wang, J Ark, A Rothrock, GM Borgo, GR Kimmerly, JH Jung, V Allain, JR Hamilton, A Baldwin, R Stickels, S Wyman, SH Khan, S Lang, D Marsh, N Almudhfar, C Novick, Y Mortazavi, S Zhang, MM AbdElwakil, LR Sandoval, S Hwang, SN Chu, H Jung, C Liu, D Sharma, T McCreary, Z Li, AT Satpathy, J Carnevale, RL Rutishauser, MK Cromer, KT Roybal, SE Dodgson, JA Doudna, A Asokan, J Eyquem. In vivo site-specific engineering to reprogram T cells. Nature652, 712–721 (2026)

2025

T Liu, M Zhang, T Farsh, H Li, A Kishishita, A Barpanda, SG Leung, J Zhu, H Jung, JT Hua, X Zhu, AB Kim, YA Goo, M Son, J Kim, A Subramanian, M Sjöström, KC Fuh, JS Chapman, J Carnevale, LA Gilbert, A Lakkaraju, PM Bruno, D Quigley, AP Wiita, FY Feng, CJ DeSelm. Exploitable mechanisms of antibody and CAR mediated macrophage cytotoxicity. Nat Commun16, 5616 (2025)

‍

L Goudy, A Ha, AA Borah, JM Umhoefer, L Chow, C Tran, A Winters, A Talbot, R Hernandez, Z Li, S Subramanya, A Arab, N Kale, JHJ Lee, JJ Muldoon, C Liu, R Schmidt, P Santangelo, J Carnevale, J Eyquem, BR Shy, A Marson, LA Gilbert. Integrated epigenetic and genetic programming of primary human T cells. Nat Biotechnol (2025)

‍

2024

MM Arce, JM Umhoefer, N Arang, S Kasinathan, JW Freimer, Z Steinhart, H Shen, MTN Pham, M Ota, A Wadhera, R Dajani, D Dorovskyi, YY Chen, Q Liu, Y Zhou, DL Swaney, K Obernier, BR Shy, J Carnevale, AT Satpathy, NJ Krogan, JK Pritchard, A Marson. Central control of dynamic gene circuits governs T cell rest and activation. Nature 637, 930–939 (2025).

2023

F Blaeschke, YY Chen, R Apathy, B Daniel, AY Chen, PA Chen, K Sandor, W Zhang, Z Li, CT Mowery, TN Yamamoto, WA Nyberg, A To, R Yu, R Bueno, MC Kim, R Schmidt, DB Goodman, T Feuchtinger, J Eyquem, CJ Ye, J Carnevale, AT Satpathy, E Shifrut, TL Roth, A Marson.. Modular pooled discovery of synthetic knockin sequences to program durable cell therapies. Cell. (19). (4216-4234) (2023)

‍

2022

J Carnevale, E Shifrut, N Kale, WA Nyberg, F Blaeschke, Y Chen, Z Li, SP Bapat, ME Diolaiti, P O’Leary, S Vedova, J Belk, B Daniel, TL Roth, S Bachl, AA Anido, D Haydar, M Luetke-Eversloh, M Born-Bony, B Hegde, S Kogan3, T Feuchtinger, H Okada, A Satpathy, K Shannon, S Gottschalk, J Eyquem, G Krenciute, Alan Ashworth, Alexander Marson. RASA2 ablation in T cells boosts antigen sensitivity and long-term function. Nature (2022).
‍

JA Belk, W Yao, N Ly, KA Freitas, YT Chen, Q Shi, AM Valencia, E Shifrut, N Kale, KE Yost, CV Duffy, B Daniel, MA Hwee, Z Miao, A Ashworth, CL Mackall, A Marson, J Carnevale, SA Vardhana, AT Satpathy. Genome-wide CRISPR screens of T cell exhaustion identify chromatin remodeling factors that limit T cell persistence. Cancer Cell, (22):00231-8 (2022).
‍

JR Byrnes, AM Weeks, E Shifrut, J Carnevale, L Kirkemo, A Ashworth, A Marson, JA Wells. Hypoxia Is a Dominant Remodeler of the Effector T Cell Surface Proteome Relative to Activation and Regulatory T Cell Suppression. Mol Cell Proteomics. (4):100217 (2022).

2021

ES Tsang, EJ Walker, J Carnevale, GA Fisher, AH Ko. Durable response after immune checkpoint inhibitor-related diabetes in mismatch repair-deficient pancreatic cancer. Immunotherapy. (15):1249-1254 (2021).

2020

SS Sinha, GC Greene, KR Kelley, CP Cinar, VA Venook, AC Atreya, GJ Gordan, J Carnevale, AM Anwar, FM Feng.. International Combined Immunotherapy and Hypofractionated Radiotherapy for Metastatic Cancers Journal of Radiation Oncology. (3):e648 (2020).

2018

E Shifrut*, J Carnevale*, V Tobin, TL Roth, JM Woo, CT Bui, PJ Li, ME Diolaiti, A Ashworth, A Marson. Genome-wide CRISPR Screens in Primary Human T Cells Reveal Key Regulators of Immune Function. Cell. (7):1958-1971 (2018). *authors contributed equally.
‍

TL Roth, C Puig-Saus, R Yu, E Shifrut, J Carnevale, Li PJ, Hiatt J, Saco J, Krystofinski P, Li H, Tobin V, Nguyen DN, Lee MR, Putnam AL, Ferris AL, Chen JW, Schickel JN, Pellerin L, Carmody D, Alkorta-Aranburu G, Del Gaudio D, Matsumoto H, Morell M, Mao Y, Cho M, Quadros RM, Gurumurthy CB, Smith B, Haugwitz M, Hughes SH, Weissman JS, Schumann K, Esensten JH, May AP, Ashworth A, Kupfer GM, Greeley SAW, Bacchetta R, Meffre E, Roncarolo MG, Romberg N, Herold KC, Ribas A, Leonetti MD, Marson A. Reprogramming human T cell function and specificity with non-viral genome targeting. Nature. (7714):405-409 (2018).
‍

J Carnevale, KA Ko. Targeting the Tumor Microenvironment. Current and Emerging Therapies in Pancreatic Cancer. 235-256 (2018).

BEFORE 2017

J Carnevale, AH Ko. MM-398 (nanoliposomal irinotecan): emergence of a novel therapy for the treatment of advanced pancreatic cancer. Future Oncol. (4):453-64 (2016).

‍

J Carnevale, JL Rubenstein. The Challenge of Primary Central Nervous System Lymphoma. Hematol Oncol Clin North Am. (6):1293-1316 (2016).

J Carnevale, A Ashworth. Assessing the Significance of BRCA1 and BRCA2 Mutations in Pancreatic Cancer. J Clin Oncol. (28):3080-1 (2015).

‍

R Renella, J Carnevale, KA Schneider, JL Hornick, HQ Rana, KA Janeway. Exploring the association of succinate dehydrogenase complex mutations with lymphoid malignancies. Fam Cancer. (3):507-11 (2014).

‍

J Carnevale, L Ross, A Puissant, V Banerji, RM Stone, DJ DeAngelo, KN Ross, K Stegmaier. SYK regulates mTOR signaling in AML. Leukemia. (11):2118-28 (2013).